BIO-RAD LABORATORIES -CL B (BIO.B) Fundamental Analysis & Valuation
NYSE:BIO.B • US0905721082
268.55 USD
+0.06 (+0.02%)
Last: Mar 12, 2026, 08:25 PM
This BIO.B fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
Taking everything into account, BIO.B scores 5 out of 10 in our fundamental rating. BIO.B was compared to 57 industry peers in the Life Sciences Tools & Services industry. BIO.B is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO.B has a correct valuation and a medium growth rate.
1. BIO.B Profitability Analysis
1.1 Basic Checks
- BIO.B had positive earnings in the past year.
- In the past year BIO.B had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: BIO.B reported negative net income in multiple years.
- Each year in the past 5 years BIO.B had a positive operating cash flow.
1.2 Ratios
- BIO.B's Return On Assets of 7.18% is amongst the best of the industry. BIO.B outperforms 85.96% of its industry peers.
- BIO.B's Return On Equity of 10.20% is amongst the best of the industry. BIO.B outperforms 80.70% of its industry peers.
- BIO.B has a better Return On Invested Capital (2.02%) than 63.16% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 11.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROIC | 2.02% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
1.3 Margins
- With an excellent Profit Margin value of 29.42%, BIO.B belongs to the best of the industry, outperforming 98.25% of the companies in the same industry.
- BIO.B's Profit Margin has declined in the last couple of years.
- With a decent Operating Margin value of 10.30%, BIO.B is doing good in the industry, outperforming 71.93% of the companies in the same industry.
- BIO.B's Operating Margin has declined in the last couple of years.
- The Gross Margin of BIO.B (52.01%) is better than 63.16% of its industry peers.
- BIO.B's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% |
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
2. BIO.B Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO.B is destroying value.
- Compared to 1 year ago, BIO.B has less shares outstanding
- The number of shares outstanding for BIO.B has been reduced compared to 5 years ago.
- The debt/assets ratio for BIO.B has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 3.07 indicates that BIO.B is not in any danger for bankruptcy at the moment.
- With a decent Altman-Z score value of 3.07, BIO.B is doing good in the industry, outperforming 64.91% of the companies in the same industry.
- The Debt to FCF ratio of BIO.B is 3.21, which is a good value as it means it would take BIO.B, 3.21 years of fcf income to pay off all of its debts.
- BIO.B has a Debt to FCF ratio of 3.21. This is amongst the best in the industry. BIO.B outperforms 84.21% of its industry peers.
- BIO.B has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
- BIO.B's Debt to Equity ratio of 0.16 is in line compared to the rest of the industry. BIO.B outperforms 57.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Altman-Z | 3.07 |
ROIC/WACC0.19
WACC10.57%
2.3 Liquidity
- A Current Ratio of 5.62 indicates that BIO.B has no problem at all paying its short term obligations.
- The Current ratio of BIO.B (5.62) is better than 84.21% of its industry peers.
- BIO.B has a Quick Ratio of 4.19. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
- BIO.B has a Quick ratio of 4.19. This is in the better half of the industry: BIO.B outperforms 77.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 |
3. BIO.B Growth Analysis
3.1 Past
- BIO.B shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
- The Earnings Per Share has been decreasing by -1.19% on average over the past years.
- BIO.B shows a small growth in Revenue. In the last year, the Revenue has grown by 0.65%.
- Measured over the past years, BIO.B shows a small growth in Revenue. The Revenue has been growing by 0.29% on average per year.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
3.2 Future
- BIO.B is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.58% yearly.
- BIO.B is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.54% yearly.
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. BIO.B Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 27.07, the valuation of BIO.B can be described as expensive.
- BIO.B's Price/Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 68.42% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 25.71, BIO.B is valued at the same level.
- A Price/Forward Earnings ratio of 25.89 indicates a quite expensive valuation of BIO.B.
- BIO.B's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO.B is cheaper than 68.42% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of BIO.B to the average of the S&P500 Index (23.82), we can say BIO.B is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.07 | ||
| Fwd PE | 25.89 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, BIO.B is valued cheaply inside the industry as 84.21% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.35 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO.B does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of BIO.B may justify a higher PE ratio.
PEG (NY)5.92
PEG (5Y)N/A
EPS Next 2Y7.58%
EPS Next 3Y7.11%
5. BIO.B Dividend Analysis
5.1 Amount
- No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIO.B Fundamentals: All Metrics, Ratios and Statistics
NYSE:BIO.B (3/12/2026, 8:25:01 PM)
268.55
+0.06 (+0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12 2026-02-12/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners90.44%
Inst Owner Change-2.11%
Ins Owners8.17%
Ins Owner ChangeN/A
Market Cap7.25B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target342.51 (27.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)-5.79%
PT rev (3m)-5.79%
EPS NQ rev (1m)-20.96%
EPS NQ rev (3m)-21.27%
EPS NY rev (1m)1.2%
EPS NY rev (3m)-0.1%
Revenue NQ rev (1m)-2.46%
Revenue NQ rev (3m)-2.59%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.07 | ||
| Fwd PE | 25.89 | ||
| P/S | 2.81 | ||
| P/FCF | 19.35 | ||
| P/OCF | 13.62 | ||
| P/B | 0.97 | ||
| P/tB | 1.08 | ||
| EV/EBITDA | N/A |
EPS(TTM)9.92
EY3.69%
EPS(NY)10.37
Fwd EY3.86%
FCF(TTM)13.88
FCFY5.17%
OCF(TTM)19.72
OCFY7.34%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)5.92
PEG (5Y)N/A
Graham Number248.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.18% | ||
| ROE | 10.2% | ||
| ROCE | 2.65% | ||
| ROIC | 2.02% | ||
| ROICexc | 2.38% | ||
| ROICexgc | 2.62% | ||
| OM | 10.3% | ||
| PM (TTM) | 29.42% | ||
| GM | 52.01% | ||
| FCFM | 14.5% |
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 3.21 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.1% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 49.3% | ||
| Current Ratio | 5.62 | ||
| Quick Ratio | 4.19 | ||
| Altman-Z | 3.07 |
F-Score5
WACC10.57%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.57%
EPS Next 2Y7.58%
EPS Next 3Y7.11%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year1.81%
Revenue Next 2Y2.49%
Revenue Next 3Y2.54%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.85%
EBIT Next 3Y17.21%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%
BIO-RAD LABORATORIES -CL B / BIO.B FAQ
What is the ChartMill fundamental rating of BIO-RAD LABORATORIES -CL B (BIO.B) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BIO.B.
Can you provide the valuation status for BIO-RAD LABORATORIES -CL B?
ChartMill assigns a valuation rating of 4 / 10 to BIO-RAD LABORATORIES -CL B (BIO.B). This can be considered as Fairly Valued.
How profitable is BIO-RAD LABORATORIES -CL B (BIO.B) stock?
BIO-RAD LABORATORIES -CL B (BIO.B) has a profitability rating of 6 / 10.
How financially healthy is BIO-RAD LABORATORIES -CL B?
The financial health rating of BIO-RAD LABORATORIES -CL B (BIO.B) is 8 / 10.